Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.

BMC health services research - 13 Jan 2021

Biskupiak Joseph, Unni Sudhir, Telford Claire, Yoo Minkyoung, Ye Xiangyang, Deka Rishi, Brixner Diana, Stenehjem David

Abstract excerpt

BACKGROUND: Breast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health care and breast cancer-related charges by BRCA status (BRCAm vs. BRCAwt), receptor status (HER2+ vs. HER2-), and treatment setting (neoadjuvant vs. adjuvant). METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Delivery of Health Care

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 33435985
DOI: 10.1186/s12913-020-06038-z
PMCID: PMC7805040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.PMID 33435985Read ↗

Estimation of Healthcare-related Charges in Women with BRCA Mutations and Breast Cancer Semantic proximity Read ↗

Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

BRCA testing and outcomes in women with breast cancer.Semantic proximity Read ↗

Financial toxicity in BRCA1 and BRCA2 carriers.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.Semantic proximity Read ↗

Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity Read ↗

Factors Associated with Financial Toxicity in Patients with Breast Cancer in Japan: A Comparison of Patient and Physician PerspectivesSemantic proximity Read ↗

Costs of Breast Cancer Treatment Incurred by Women in VietnamSemantic proximity Read ↗

Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in ChinaSemantic proximity Read ↗

Influence of Health Insurance Type on the Access of Cancer Patients to Ramucirumab Therapy Using <em>All of Us</em> DatabaseSemantic proximity Read ↗

Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.